<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">No clinically significant effect on QT prolongation was observed in healthy subjects at therapeutic doses. Some patients taking tocilizumab experienced rapid increases in blood pressure and low-density lipoprotein cholesterol [
 <xref ref-type="bibr" rid="CR65">65</xref>]. However, according to the findings of the ENTRACTE study that compared the cardiovascular safety in patients with rheumatoid arthritis receiving either tocilizumab or etanercept [
 <xref ref-type="bibr" rid="CR66">66</xref>], there were no significant increases in stroke, heart attack, heart failure hospitalization, or cardiac death.
</p>
